One ATR Kinase Inhibitor Mechanism, Three Gateways: What a Biomarker-Selected Oncology Candidate's Regulatory Path Reveals About Parallel Health Canada, FDA, and EMA Clinical Trial Authorization

Ataxia telangiectasia and Rad3-related protein (ATR) kinase inhibitors are investigational small molecules that target a central regulator of the cellular DNA damage response, exploiting the observation that tumours carrying certain loss-of-function alterations in DNA damage response pathways may be more vulnerable to ATR inhibition than tumours without these alterations. This article uses a hypothetical multicentre Phase 1/2 clinical trial of an ATR kinase inhibitor candidate, sponsored by a fictional company, to compare the Clinical Trial Application (CTA) process required by Health Canada, the Investigational New Drug (IND) process required by the U.S. Food and Drug Administration, and the Clinical Trial Application process required by the European Medicines Agency under Regulation (EU) No 536/2014, using a biomarker-selected advanced solid tumour population as the illustrative scenario. The comparison traces how the Common Technical Document's harmonized Modules 2 through 5 carry the shared scientific case across all three regions while the biomarker selection strategy itself, the companion diagnostic or laboratory-developed test used to identify eligible patients, introduces specific administrative and scientific considerations in each region's review. The article addresses the operational challenges specific to a biomarker-driven oncology program conducted across these three jurisdictions, the ways artificial intelligence tools are used, and can responsibly be used, in preparing and administering this kind of regulatory package, and closes with recommendations for regulatory operations teams managing DNA damage response-targeted oncology candidates across Canada, the United States, and the European Union.Keywords: ATR kinase inhibitor; DNA damage response; biomarker-selected oncology trial; Clinical Trial Application; Investigational New Drug; Regulation (EU) No 536/2014; regulatory artificial intelligence